Shire buys ViroPharma in $4.2 billion deal (Update)

The drugmaker Shire PLC plans to strengthen its rare disease treatment portfolio by spending $4.2 billion in cash to buy the biopharmaceutical company ViroPharma Inc.

The Dublin-based drugmaker said Monday it will pay $50 for each share of ViroPharma, which is based in Exton, Pa. That represents a 27 percent premium on the U.S. company's closing price Friday, the last trading day before the deal was announced.

Shares of ViroPharma soared before markets opened and after the deal was announced, while Shire's U.S.-traded stock also climbed.

ViroPharma focuses on serious diseases with few, if any, available therapies. Its products include Cinryze, which is used to prevent and treat attacks of hereditary angioedema, a rare genetic disorder that can cause dangerous swelling of the throat or larynx.

It also makes the seizure drug Buccolam and antibiotic Vancocin.

The company generated $428 million in worldwide revenue last year.

ViroPharma said last month that U.S. sales of Cinryze, which accounts for most of its revenue, climbed 22 percent in the third quarter to $102.2 million. It expects North American sales for the treatment to total $405 million this year.

Shire said Cinryze will act as a complement to one if its drugs, Firazyr, which treats acute hereditary angioedema attacks.

ViroPharma also is developing maribavir, a potential treatment for a virus that can lead to serious disease or death in people with compromised immune systems. The experimental drug has received an orphan drug designation from both European and U.S. regulators. That could lead to market exclusivity if the drug is approved.

The companies expect the deal to close by the end of this year, next year's first quarter or soon after that.

ViroPharma shares soared nearly 26 percent, or $10.19, to $49.57 Monday in premarket trading. The stock has more than doubled after closing 2012 at $22.76.

U.S.-traded shares of Shire climbed 3.7 percent, or $4.92, to $139.32.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Research Lends Hope for Patients With Rare Swelling Disease

Aug 10, 2010

(PhysOrg.com) -- The results of two recent clinical trials offer promising treatments for sufferers of the rare genetic disease hereditary angiodema, says Jonathan Bernstein, MD, an internationally recognized allergy specialist ...

FDA relents from midodrine withdrawal plan

Sep 06, 2010

(AP) -- Federal regulators have backed off a plan to remove a Shire PLC low blood-pressure treatment from the market after warning in August that the drug has not been proven effective.

Huge yawn locks jaw, chokes man

Nov 19, 2007

A British man was rushed to the hospital after his monster yawn locked his jaw, blocking his ability to breathe or swallow.

Recommended for you

Medical charity warns India over patent rules

Jan 21, 2015

Doctors without Borders on Wednesday warned the Indian government not to bow to US pressure to amend patent regulations that allow millions access to affordable medicines, ahead of a visit by President Barack Obama.

Why are some generic drugs getting so expensive?

Jan 21, 2015

More than eight out of every 10 prescriptions dispensed in the US is generic. This growth is due to a large number of top-selling drugs going off patent over the past decade, as well as innovations in t ...

Supreme Court sides with Teva in drug dispute

Jan 20, 2015

The Supreme Court on Tuesday sided with Teva Pharmaceutical Industries Ltd. in the company's high-profile patent dispute with rival firms over the top-selling multiple sclerosis drug.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.